Acute low back pain: did the new guidelines overlook a simple treatment option?

Low back pain is among the most common reasons people seek medical care. Most acute episodes improve without invasive intervention, but pain can substantially restrict movement, disrupt sleep, and interfere with everyday activities. Effective early treatment should therefore accomplish two distinct goals: reduce suffering and preserve mobility without imposing unnecessary biological risks.

A multidisciplinary clinical practice guideline from the American Academy of Pain Medicine, published in Pain Medicine in 2026, reinforces conservative care principles. It recommends patient education, continued low-impact movement, superficial heat, and oral nonsteroidal anti-inflammatory drugs, while discouraging prolonged bed rest, unnecessary imaging, and routine opioid prescribing.

Yet an important therapeutic option receives little attention in the clinical recommendations: topical analgesics, including nonsteroidal anti-inflammatory drug formulations, capsaicin preparations, and other locally acting creams, ointments, and patches.

Why should pharmacologic treatment almost universally begin with systemic medication when pain might be addressed locally?

Topical nonsteroidal anti-inflammatory drugs deliver active medication to underlying tissues while producing substantially lower systemic exposure than oral formulations. This pharmacokinetic difference is particularly meaningful for older adults and patients with preexisting gastrointestinal, cardiovascular, or renal vulnerabilities. The anatomical depth of the lumbar spine—where pain may originate in deep paraspinal muscles, facet joints, or disc complexes—presents a real pharmacokinetic hurdle compared to superficial joints like the knee or wrist. Even so, superficial myofascial strain and soft-tissue irritation remain frequent contributors to acute back episodes.

In 2020, the American College of Physicians and the American Academy of Family Physicians jointly recommended topical nonsteroidal anti-inflammatory drugs as first-line pharmacologic therapy for acute, non-low back musculoskeletal pain. Low back pain was explicitly excluded from that clinical guideline because of a lack of qualifying dedicated trials. Consequently, guideline panels following strict evidence-synthesis protocols remain silent on topical formulations in the lumbar region, even though clinical practice often bridges this evidentiary gap.

Capsaicin-containing preparations introduce another distinct mechanism. Capsaicin acts as an agonist at transient receptor potential vanilloid 1 receptors on primary sensory afferents, initially producing localized burning or erythema before desensitizing nociceptive fibers with repeated use. In a randomized controlled trial involving 320 patients with chronic nonspecific low back pain, 67 percent of patients treated with a standardized capsicum plaster achieved at least a 30 percent reduction in pain, compared with 49 percent receiving placebo. While chronic pain trial results cannot be directly extrapolated to self-limiting acute episodes, they demonstrate that local sensory modulation in the lumbar region warrants formal clinical investigation.

Other counterirritant preparations containing menthol, camphor, or methyl salicylate function through distinct thermoreceptor and sensory mechanisms. They should not be considered interchangeable, and their clinical evidence remains less consistent. Moreover, topical application does not equal absence of risk: local dermal irritation, chemical burns, contact allergies, and rare systemic absorption remain possible. Critically, because guidelines explicitly advise superficial heat, patients must be warned never to apply heating pads over topical analgesics, as heat accelerates transdermal absorption and markedly elevates the risk of severe burns and toxicity.

The central issue is not whether topical treatments are universally effective or should displace exercise, education, or physical modalities. Rather, clinical guidelines that emphasize conservative, risk-minimizing management should evaluate local pharmacological options, clarify their rationale, and highlight the evidentiary gaps that clinical trials have yet to fill.

A lack of dedicated randomized trials specifically addressing acute low back pain is not proof of therapeutic failure. At the same time, proven efficacy in peripheral joints does not guarantee success in deep spinal pathology.

Comprehensive clinical recommendations should acknowledge both realities.

The primary objective in managing acute low back pain is not simply suppressing discomfort or passively waiting for natural resolution. It is to facilitate functional recovery while minimizing the biological burden of therapy. Topical analgesics offer a practical, low-risk component of individualized care, especially when systemic pharmacotherapy poses clear hazards.

References

1. Skelly AC, Dettori JR, Brodt ED, et al. Assessment and Treatment of Acute Low Back Pain: A Multidisciplinary Clinical Practice Guideline From the American Academy of Pain Medicine. Pain Medicine. 2026. DOI: 10.1093/pm/pnag110.

2. Qaseem A, McLean RM, O'Gurek D, et al. Nonpharmacologic and Pharmacologic Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries in Adults: A Clinical Guideline From the American College of Physicians and American Academy of Family Physicians. Annals of Internal Medicine. 2020;173(9):739–748. DOI: 10.7326/M19-3602.

3. Frerick H, Keitel W, Volkmann R, Kuhn D. Topical treatment of chronic low back pain with a capsicum plaster: a randomized, double-blind, placebo-controlled study. Pain. 2003;106(1-2):59–64. DOI: 10.1016/S0304-3959(03)00278-1.

More about this topic can be found in our books on Our Books on Google Play and related articles in the Index.

Mykola Iabluchanskyi together with Andriy Yabluchanskiy